ABIVAX SA ORDINARY SHARES FRANCE (OTCMKTS:AAVXF) Shorts Declined By 2.94%

It was noted a decrease on ABIVAX SA ORDINARY SHARES FRANCE (OTCMKTS:AAVXF)’s short interest with 2.94%. FINRA published short interest of AAVXF’s total 3,300 shares. Previously was reported down change of 2.94% from 3,400 shares. Former AAVXF’s position will need 33 days to recover. It has 100 average volume.

The stock decreased 11.48% or $1.39 during the last trading session, reaching $10.72.Currently ABIVAX Société Anonyme is after 0.00% change in last December 8, 2017. AAVXF has also 100 shares volume. The stock underperformed the S&P 500 by 15.62%.

ABIVAX Société Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America.The company has $100.56 million market cap. The Company’s principal products include ABX 464 that is in Phase II clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS; ABX 203, a therapeutic vaccine candidate, which is in Phase IIb/III clinical trials for the treatment of chronic hepatitis B; and ABX 196, an immunostimulant/adjuvant candidate that has completed Phase I clinical trials for iNKT cell agonists.Currently it has negative earnings. It also develops vaccines for typhoid, meningitis B and C, and leptospirosis.

A couple more ABIVAX Société Anonyme (OTCMKTS:AAVXF) news were released by: Seekingalpha.com which released on May 25, 2017 “Abivax: A Biotech With Blockbuster Potential – Seeking Alpha”, also Seekingalpha.com on September 05, 2018 released “Abivax UC candidate shows positive action in mid-stage study – Seeking Alpha”, the next Seekingalpha.com is “Abivax Not Getting Ahead Of Itself In HIV Chase – Seeking Alpha” on May 22, 2017. Seekingalpha.com has article titled “Abivax soars on HIV results – Seeking Alpha”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.